You are viewing a historical snapshot of United States (NYSE / Nasdaq). These figures are a preview to show what TradeTidings covers. Live, continuously updated United States sentiment and stock impact is a Pro feature.
Get live United States data with ProMost active sentiment
Symbols with the most news coverage right now.
Market sentiment timeline
Day, week, and month sentiment history for the whole United States market.
Sentiment timeline
How news sentiment on the United States market has built up over time. Each bar sums the direction of every story TradeTidings published in the period, weighted by how influential we rated it, not just a plain count, so a single high-influence negative story can outweigh several small positive ones. Hover a bar for its exact figures, or click one to filter the stories below to that period. Our own original analysis, not a copied index or a price chart, and not a prediction.
Latest Tidings
The newest stories and the stocks they move, grouped by sector.
Generac Lands Second Data Center Power Deal, $700 Million Committed for 2027
Generac secured its second large data center power deal, with $700 million committed for 2027, extending its push beyond home generators.
Rocket Lab Wins $266 Million US Space Force Contract
Rocket Lab was awarded a $266 million US Space Force contract, a large government win for the space and launch company.
Ferrovial Stock: Infrastructure Group Tops H1 2026 Revenue Forecasts
Ferrovial reported first-half 2026 revenue that came in ahead of forecasts, with its toll-road and airport infrastructure assets driving the top line.
FAA Flags 737 MAX Seat Fault for Inspection: Boeing Stock in Focus
The FAA says certain 737 MAX seats could be faulty and need inspection, adding another quality checkpoint to Boeing's best-selling jet program.
Broadcom Signs $200 Billion AI Chip Agreement in Major Custom Silicon Win
Broadcom announced a roughly $200 billion AI agreement, a large commitment landing in its custom chip and networking business.
Teradyne Q2 Earnings Beat Estimates as Chip Test Demand Grows
Teradyne beat second-quarter earnings estimates with revenue up year over year, helped by demand for its semiconductor test equipment.
Cognizant Raises Full-Year Profit Forecast on Financial Services Growth
Cognizant lifted its full-year profit forecast, pointing to strong growth in its financial services business as a driver.
Flex Stock in Focus as Strong Q2 Results Fail to Lift Shares
Flex reported strong second-quarter results, but its shares fell, putting the focus on guidance and expectations for the contract manufacturer.
Baker Hughes Lands Large Gas Turbine Order From Texas Power Developer
Baker Hughes secured a large gas turbine order from a Texas power developer, a win for its industrial and energy technology business.
Expand Energy Stock in Focus as Q2 Profit Tops Views and Shares Rise
Expand Energy, the largest US natural gas producer, topped second-quarter profit views and its shares rose, drawing focus to its gas output and pricing.
Oil Prices Spike After Iran Strikes: ExxonMobil and Chevron Stocks in Focus
Crude oil prices spiked after strikes on Iran, lifting energy producers, with ExxonMobil and Chevron drawing the most direct attention.
Kinder Morgan Stock: Record Q2 Results Highlight Pipeline Demand
Kinder Morgan posted record second quarter results, underscoring steady demand for its natural gas pipeline network even as one analyst keeps a cautious view on the stock.
Humana Stock Falls as Q2 Report Holds Adjusted Outlook and Cuts GAAP EPS View
Humana shares fell after the insurer kept its adjusted profit outlook flat and lowered its GAAP earnings-per-share view for the year.
Biogen Stock in Focus as Q2 Earnings Beat and New Drugs Lift Guidance
Biogen beat second-quarter earnings estimates and raised its 2026 guidance as newer drugs helped drive sales beyond its legacy franchises.
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End Its Marathon Legal Fight
Johnson & Johnson has proposed a $5.5 billion settlement to resolve years of talc litigation, replacing an open-ended legal risk with a fixed, known cost.
AbbVie Stock: Epcoritamab Trial Setback Raises Questions on Blood Cancer Pipeline
AbbVie hit a setback in a clinical trial for epcoritamab, a blood cancer drug it counts on to help offset declining Humira sales.
Track the stocks you care about
Build a watchlist, get sentiment alerts when the news turns, and see the full picture for every symbol.